179 related articles for article (PubMed ID: 9241078)
1. Interstitial iodine-125 radiation without adjuvant therapy in the treatment of clinically localized prostate carcinoma.
Ragde H; Blasko JC; Grimm PD; Kenny GM; Sylvester JE; Hoak DC; Landin K; Cavanagh W
Cancer; 1997 Aug; 80(3):442-53. PubMed ID: 9241078
[TBL] [Abstract][Full Text] [Related]
2. Ten-year disease free survival after transperineal sonography-guided iodine-125 brachytherapy with or without 45-gray external beam irradiation in the treatment of patients with clinically localized, low to high Gleason grade prostate carcinoma.
Ragde H; Elgamal AA; Snow PB; Brandt J; Bartolucci AA; Nadir BS; Korb LJ
Cancer; 1998 Sep; 83(5):989-1001. PubMed ID: 9731904
[TBL] [Abstract][Full Text] [Related]
3. Prostate specific antigen findings and biopsy results following interactive ultrasound guided transperineal brachytherapy for early stage prostate carcinoma.
Stock RG; Stone NN; DeWyngaert JK; Lavagnini P; Unger PD
Cancer; 1996 Jun; 77(11):2386-92. PubMed ID: 8635111
[TBL] [Abstract][Full Text] [Related]
4. Five-year biochemical outcome following permanent interstitial brachytherapy for clinical T1-T3 prostate cancer.
Merrick GS; Butler WM; Galbreath RW; Lief JH
Int J Radiat Oncol Biol Phys; 2001 Sep; 51(1):41-8. PubMed ID: 11516849
[TBL] [Abstract][Full Text] [Related]
5. Comparison of biochemical disease-free survival of patients with localized carcinoma of the prostate undergoing radical prostatectomy, transperineal ultrasound-guided radioactive seed implantation, or definitive external beam irradiation.
Stokes SH
Int J Radiat Oncol Biol Phys; 2000 Apr; 47(1):129-36. PubMed ID: 10758314
[TBL] [Abstract][Full Text] [Related]
6. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer.
D'Amico AV; Whittington R; Malkowicz SB; Schultz D; Blank K; Broderick GA; Tomaszewski JE; Renshaw AA; Kaplan I; Beard CJ; Wein A
JAMA; 1998 Sep; 280(11):969-74. PubMed ID: 9749478
[TBL] [Abstract][Full Text] [Related]
7. Prostate specific antigen-monitored combination radiotherapy for patients with prostate cancer. I-125 implant followed by external-beam radiation.
Critz FA; Tarlton RS; Holladay DA
Cancer; 1995 May; 75(9):2383-91. PubMed ID: 7536126
[TBL] [Abstract][Full Text] [Related]
8. Improved biochemical relapse-free survival with increased external radiation doses in patients with localized prostate cancer: the combined experience of nine institutions in patients treated in 1994 and 1995.
Kupelian P; Kuban D; Thames H; Levy L; Horwitz E; Martinez A; Michalski J; Pisansky T; Sandler H; Shipley W; Zelefsky M; Zietman A
Int J Radiat Oncol Biol Phys; 2005 Feb; 61(2):415-9. PubMed ID: 15667961
[TBL] [Abstract][Full Text] [Related]
9. Risk profiles to predict PSA relapse-free survival for patients undergoing permanent prostate brachytherapy.
Potters L; Cha C; Oshinsky G; Venkatraman E; Zelefsky M; Leibel S
Cancer J Sci Am; 1999; 5(5):301-6. PubMed ID: 10526671
[TBL] [Abstract][Full Text] [Related]
10. Permanent interstitial brachytherapy in younger patients with clinically organ-confined prostate cancer.
Merrick GS; Butler WM; Wallner KE; Galbreath RW; Adamovich E
Urology; 2004 Oct; 64(4):754-9. PubMed ID: 15491715
[TBL] [Abstract][Full Text] [Related]
11. A comparison of external beam radiation therapy versus radical prostatectomy for patients with low risk prostate carcinoma diagnosed, staged, and treated at a single institution.
Martinez AA; Gonzalez JA; Chung AK; Kestin LL; Balasubramaniam M; Diokno AC; Ziaja EL; Brabbins DS; Vicini FA
Cancer; 2000 Jan; 88(2):425-32. PubMed ID: 10640977
[TBL] [Abstract][Full Text] [Related]
12. Three-year results of treatment for prostate cancer with low-dose rate temporary iridium-192 brachytherapy.
Momma T; Saito S; Toya K; Yorozu A; Dokiya T; Murai M
Int J Urol; 2006 Mar; 13(3):218-23. PubMed ID: 16643612
[TBL] [Abstract][Full Text] [Related]
13. Impact of supplemental external beam radiotherapy and/or androgen deprivation therapy on biochemical outcome after permanent prostate brachytherapy.
Merrick GS; Butler WM; Wallner KE; Galbreath RW; Lief JH; Allen Z; Adamovich E
Int J Radiat Oncol Biol Phys; 2005 Jan; 61(1):32-43. PubMed ID: 15629591
[TBL] [Abstract][Full Text] [Related]
14. Chemical disease-free survival in localized carcinoma of prostate treated with external beam irradiation: comparison of American Society of Therapeutic Radiology and Oncology Consensus or 1 ng/mL as endpoint.
Perez CA; Michalski JM; Lockett MA
Int J Radiat Oncol Biol Phys; 2001 Apr; 49(5):1287-96. PubMed ID: 11286836
[TBL] [Abstract][Full Text] [Related]
15. PSA nadir of <0.5 ng/mL following brachytherapy for early-stage prostate adenocarcinoma is associated with freedom from prostate-specific antigen failure.
Ko EC; Stone NN; Stock RG
Int J Radiat Oncol Biol Phys; 2012 Jun; 83(2):600-7. PubMed ID: 21985944
[TBL] [Abstract][Full Text] [Related]
16. Median 5 year follow-up of 125iodine brachytherapy as monotherapy in men agedGómez-Iturriaga Piña A; Crook J; Borg J; Lockwood G; Fleshner N
Urology; 2010 Jun; 75(6):1412-6. PubMed ID: 20035986
[TBL] [Abstract][Full Text] [Related]
17. Calculated prostate carcinoma volume: The optimal predictor of 3-year prostate specific antigen (PSA) failure free survival after surgery or radiation therapy of patients with pretreatment PSA levels of 4-20 nanograms per milliliter.
D'Amico AV; Whittington R; Kaplan I; Beard C; Schultz D; Malkowicz SB; Wein A; Tomaszewski JE; Coleman CN
Cancer; 1998 Jan; 82(2):334-41. PubMed ID: 9445191
[TBL] [Abstract][Full Text] [Related]
18. Undetectable prostate specific antigen at 6-12 months: a new marker for early success in hormonally treated patients after prostate brachytherapy.
Miller N; Smolkin ME; Bissonette E; Theodorescu D
Cancer; 2005 Jun; 103(12):2499-506. PubMed ID: 15852361
[TBL] [Abstract][Full Text] [Related]
19. Influence of body mass index on biochemical outcome after permanent prostate brachytherapy.
Merrick GS; Butler WM; Wallner KE; Galbreath RW; Allen Z; Lief JH; Adamovich E
Urology; 2005 Jan; 65(1):95-100. PubMed ID: 15667872
[TBL] [Abstract][Full Text] [Related]
20. Modern prostate brachytherapy. Prostate specific antigen results in 219 patients with up to 12 years of observed follow-up.
Ragde H; Korb LJ; Elgamal AA; Grado GL; Nadir BS
Cancer; 2000 Jul; 89(1):135-41. PubMed ID: 10897010
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]